Physician profile
Daniel Anderson
NPI 1104112705
$2,116.13
in general payments reported to CMS, 2019-2025
25 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $1,342 · 2022: $253 · 2023: $168 · 2024: $105 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.94 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $306.30 | 2020-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $304.33 | 2021-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $145.22 | 2021-2022 | |
| Boston Scientific Corporation | $104.79 | 2021-2025 | General - Therapies |
| Amgen INC. | $99.20 | 2020-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $95.30 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $55.86 | 2021-2022 | |
| Astellas Pharma US INC | $55.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.17 | 2021 | |
| Merck Sharp & Dohme LLC | $47.19 | 2020-2021 | |
| Exeltis, USA INC. | $46.09 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $46.00 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.34 | 2021-2022 | |
| Eisai INC. | $39.57 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $36.90 | 2021-2022 | |
| Pfizer INC. | $29.48 | 2021-2022 | |
| Allergan, INC. | $27.11 | 2020 | |
| Tolmar, INC. | $23.82 | 2025 | Eligard |
| Horizon Therapeutics Plc | $22.67 | 2021 | |
| Medtronic, INC. | $18.63 | 2021 | |
| Polynovo North America LLC | $17.82 | 2024 | Novosorb Btm |
| Dexcom, INC. | $16.78 | 2021 | |
| Therapeuticsmd, INC. | $14.42 | 2020 | |
| Chiesi USA, INC. | $13.96 | 2024 | Elfabrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.